Barclays PLC Has $121,000 Position in Fractyl Health, Inc. (NASDAQ:GUTS)

Barclays PLC increased its position in shares of Fractyl Health, Inc. (NASDAQ:GUTS) by 1,754.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 47,796 shares of the company’s stock after purchasing an additional 45,219 shares during the period. Barclays PLC owned approximately 0.10% of Fractyl Health worth $121,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Jane Street Group LLC acquired a new stake in Fractyl Health during the 3rd quarter worth approximately $25,000. Rhumbline Advisers bought a new position in Fractyl Health during the 2nd quarter worth $32,000. SG Americas Securities LLC bought a new position in Fractyl Health during the 3rd quarter worth $33,000. HighTower Advisors LLC bought a new position in Fractyl Health during the 3rd quarter worth $38,000. Finally, Beta Wealth Group Inc. bought a new position in Fractyl Health during the 3rd quarter worth $44,000.

Insider Activity

In related news, CEO Harith Rajagopalan sold 96,517 shares of the business’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $2.47, for a total transaction of $238,396.99. Following the sale, the chief executive officer now owns 491,329 shares in the company, valued at $1,213,582.63. The trade was a 16.42 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Jay David Caplan sold 64,197 shares of the business’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $2.47, for a total value of $158,566.59. Following the sale, the insider now owns 153,544 shares in the company, valued at $379,253.68. This represents a 29.48 % decrease in their position. The disclosure for this sale can be found here.

Fractyl Health Price Performance

Fractyl Health stock opened at $1.90 on Thursday. The stock’s fifty day moving average price is $2.21 and its two-hundred day moving average price is $2.83. Fractyl Health, Inc. has a one year low of $1.74 and a one year high of $14.50. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.58 and a quick ratio of 5.57. The firm has a market cap of $91.39 million and a PE ratio of -0.16.

Fractyl Health (NASDAQ:GUTS) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.02. The company had revenue of $0.01 million for the quarter. As a group, research analysts expect that Fractyl Health, Inc. will post -1.66 EPS for the current fiscal year.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.